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ABSTRACT
Role of the Endocannabinoid System and Medical Cannabis
Sean I. Rasmussen
College of Nursing, BYU
Master of Science

Our bodies produce substances called endocannabinoids which attach to receptors within
the endocannabinoid system (ECS) impacting physiological processes on a daily basis. The
cannabis plant contains over 100 different cannabinoids which also manipulate the ECS.
Knowledge about these interactions have led to an increase in cannabis based pharmacological
studies. Providers should have a basic understanding about how the ECS works and how
cannabis is being used to treat certain illnesses. This article presents what is currently known
about the ECS and how cannabis based medicines impact it, as well as the current laws providers
need know regarding cannabis use.
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Introduction
Cannabis has been highly valued and used by many cultures, throughout history, for its
medicinal, euphoria, and relaxing enhancing properties. This usage dates back over 3000 years
with the report of anxiety relief with bhang (cannabis consumed as food) in ancient India1. In
2008, archeologists discovered cannabis in 2,500 year-old tombs in Eastern China. Genetic
testing of this ancient marijuana led researchers to believe that not only was the marijuana used
for treating illness but was used for its psychotropic effects and for spiritual purposes as well 2.
It was not until much later that cannabis was introduced into the United States. In 1619,
King James I ordered the Jamestown colonists to grow cannabis plants for hemp export. The
hemp fibers were used to manufacture ropes, paper, and fabric 3. In the 1850’s, medicinal
preparations became available in American pharmacies. Over the next 3 decades, recreational
use of cannabis flourished in oriental-style hashish establishments 4. It was during this time that
cannabis was labeled as both a poison and narcotic.
In 1906, the Pure Drug and Food Act was passed requiring that certain drugs, including
cannabis, be accurately labeled and states began to restrict the sale of cannabis 5. In 1937, the
Marijuana Tax Act was passed which made it illegal to possess or transfer cannabis. In 1970, the
Supreme Court determined that the Marijuana Tax Act was unconstitutional. It was during this
time Congress passed the Controlled Substance Act and listed cannabis as a Schedule 1 drug 6.
Cannabis possesses over 100 different cannabinoids and has been found to modulate
analgesia and anti-inflammatory pathways and provide neuroprotection among other functions 7.
In the 20th century, Δ9-tetrahydrocannabinol (THC) was identified as a primary bioactive
component of cannabis; this led to the discovery and cloning of endogenous cannabinoid
receptors. It was also found the body could produce naturally occurring substances, called
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endocannabinoids, which could mimic THC activity. Endocannabinoids, their receptors, and the
associated mediating enzymes for synthesis and degradation comprise the endocannabinoid
system (ECS) 8.
In the United States there are three categories of cannabinoid medicines: single molecule
drugs, cannabis-based liquid extracts, and phytocannabinoid botanicals 7. Single molecule drugs
are semi-synthetic or synthetic prescription drugs. The U.S. Food and Drug Administration
(FDA) have approved two of these and they are nabilone and dronabinol 7. The second category
of cannabis-based liquid extracts includes the botanical drug naximols which is produced by the
UK- based GW Pharmaceuticals company. This drug is currently undergoing FDA phase 3 trials.
They are looking at whether there is significant difference between naximols and placebo in
reducing pain in patients with advanced cancer 9.
The last category of cannabinoid medicines is phytocannabinoid botanicals which
includes the Schedule 1 plant Cannabis sativa 7. These are dense cannabis extracts which are
usually put into capsule or pill form. Other methods of delivery may include through sublingual
sprays, transdermal patches, suppositories and topical ointments. An example of this category is
a schedule three drug called Idrasil which is used to help alleviate pain and improve appetite 10.
With the discovery of the ECS, scientists and researchers have been petitioning to remove
the cannabis Schedule I drug restrictions so medical research can more easily be done. Current
research is studying the effects of exogenous cannabinoids in treating symptoms of epilepsy,
HIV neuropathy, chemotherapy induced nausea, anorexia, multiple sclerosis spasticity, chronic
and neuropathic pain, glaucoma intraocular pressures, and asthma-associated dyspnea 7. The
FDA has recently given approval for a study on the effect of medical cannabis on treating
military veterans with post-traumatic stress disorder 11.

Sabrina Jarvis & Sean Rasmussen & Blaine Winters 3
Currently, twenty-five states have passed laws permitting limited use of medicinal
cannabis for specific medical conditions 12. Patients receive state authorizations to procure and
self-administer medicinal cannabis under in-state medical supervision. Yet many health-care
providers feel uncomfortable providing care to these patients. Besides geographical
considerations, there continues to be a sociopolitical environment in which state laws are in
direct conflict with federal laws with potential serious legal consequences to both provider and
patient12. The purpose of this article is to educate health-care professionals about the ECS and
the research being done on medications which directly impact the ECS to reduce or alleviate
disease-associated symptoms. Additional background information will be provided on current
cannabis plant medical research and the sociopolitical factors which continue to impact both the
health care provider and patient in the decision to treat with cannabinoid medications.
ECS
The ECS is comprised of endocannabinoids (eCBs), their receptors, and the associated
mediating enzymes for synthesis and
degradation. It is a unique and complex system
with the endocannabinoids acting as the only
known retrograde synaptic neurotransmitters 13.
There are five known eCBs produced by the
body. They include: Anandamide (AEA), 2Archidonoyl glyceral (2-AG), 2-Archidonoyl
glyceral ether (noladin ether), O- Archidonoyl
ethanolamine (virodhamine), and NArachidonoyl dopamine 13. AEA and 2-AG are
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the two most commonly recognized and studied endocannabinoid ligands and are endogenous
arachidonate-based lipids 14. AEA was discovered in 1992 and helped to provide a basic
understanding of ECS neuro-modulating function. AEA’s effects occur in both the central
nervous system and the peripheral nervous system. There is less information on noladin ether,
virodhamine, and N-Arachidonoyl dopamine and their roles in the regulation of the ECS 15. It is
important to note eCBs are normally at low levels when body homeostasis is balanced. They
only begin to be synthesized in large quantities when stimulated. This activation can occur as a
response to painful stimuli, bacterial and/or viral infections, stress response, or inflammation 16.
While cannabis plant cannabinoids directly target cannabinoid Type 1 receptors (CB1Rs)
on the pre-synaptic neuron, AEA and 2-AG are produced, on demand, from lipid precursors
found in the post-synaptic neuron and released into the synaptic space (Figure 1). When
depolarization of the postsynaptic neuron occurs, the naturally influxed calcium is thought to
activate the enzyme, transacyclase. It is suggested this enzyme catalyzes the first step in the
biosynthesis of endocannabinoids by converting phosphatidylethanolamine, a phospholipid, into
N-acyl-phosphatidlethanolamine (NAPE). The endocannabinoids then travel retrograde to the
CB1 receptors on the presynaptic neuron. The bound endocannabinoids initiate a series of
biochemical reactions which lead to a decrease in inhibitory neurotransmitters (Figure 1). This
leads to the direct result of increased activity of the postsynaptic neuron. The AEA is then
rapidly inactivated by fatty acid amide hydrolase (FAAH) and the 2-AG is broken down by
monoacylglycerol lipase 17.
The primary purpose of the ECS is to provide homeostasis for many metabolic functions
such as neurotransmitter, inflammation and energy modulation. The ECS is located throughout
the entire body and is comprised of specific cannabinoid receptors.
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Cannabinoid Receptors
The cannabinoid receptors are G protein-coupled receptors which are activated by three
major groups of ligands: endocannabinoids produced by the body, cannabinoids produced from
the cannabis plant, and synthetic cannabinoids. The two principle subtypes of cannabinoid
receptors are CB1Rs and cannabinoid Type 2 receptors (CB2Rs) 18.
CB1Rs reside heavily within the central nervous system (CNS) and are well known for
their neurological effects when activated. In addition to their presences within the brain, CB1Rs
are also found within digestive organs, including the pancreas, liver, small intestines, and large
intestines. They have also been found within muscle fibers and adipocyte cells as well 16.
Although CB1Rs are scattered throughout the body their role and function within the CNS may
hold the most potential.
CB1Rs found within the hippocampus and limbic system play a significant role in the
regulation of emotions. When the hippocampus receptors are activated, cannabis users often
describe experiencing a blissful euphoria 16. Clinical data suggests endocannabinoids and CB1Rs
may modulate anxiety and depression. Augmentation of the endocannabinoid signaling has been
found to decrease depression and anxiety symptoms, whereas, if the CB1Rs are blocked, this
produces increased symptoms 19. There are also CB1Rs located in the basal ganglia and
hypothalamus, which when stimulated, help regulate appetite and gastric motility. These gastric
effects led to the development of dronabinol, a medication used to treat cancer-related anorexia
and nausea symptoms 16.
CB2Rs are found in many areas in the body and, unlike CB1Rs, have almost no
psychoactive effects when stimulated. Most are found along the spinal column or in the bone
marrow while only a few receptors are found within the brain 16. Although both CB1Rs and
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CB2Rs have been found in inflammation leukocyte mediators, CB2Rs are predominant in
leukocytes and appear to be the key mediators of cannabinoid regulation of the immune and
inflammatory systems. When the CB2Rs are blocked, there is inhibition of splenocyte production
and in vivo cell death. When macrophage CB2Rs are stimulated they inhibit proliferation and the
release of pro-inflammatory factors, and decrease phagocytosis 20. For example, in the presence
of ischemia, cardiomyocytes are subject to inflammation and eventually cellular death. In this
state CB2Rs are agonized as part of the body’s natural response. When researchers antagonized
CB2Rs during hypoxia, both inflammation and macrophage digestion was minimized 21.
CB1Rs and CB2Rs play a role in modulating pain pathways and helping to provide
analgesia. In cancer pain pathway research, cannabinoids act as analgesics in patients with
neuropathic pain and are antihyperalagesic. They have been shown to decrease painful stimuli
from sensory neurons in many animal models. There are also indications cannabinoids may
potentiate the analgesic properties of morphine and help prevent drug tolerance 22.
In neuropathic pain, cannabinoids act on peripheral and central nerve CB1Rs and
keratinocytes CB2Rs. The peripheral nociceptors CB1Rs help mediate and block painful stimuli
to the sensory neurons. CB2Rs located on the immune cells and keratinocytes stimulates βendorphin release and decreased pain stimuli through µ-opiod receptors 22.
Cannabinoids
The cannabis plant contains over 400 naturally occurring chemicals and approximately
100 cannabinoids 23. Cannabis is the root word and the scientific plant genus from which all
other names derive. There are three subspecies of cannabis including cannabis sativa, cannabis
indica, and cannabis ruderalis. Cannabis sativa is the most widely cultivated plant in the US and
abroad for both commercial and pharmaceutical uses 24.
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The cannabis plant can be broken down into four major parts which are the stems, seeds,
flowers or buds, and leaves. Hemp is obtained from the stems and is used to manufacture
clothing, rope, paper, protein supplements, beauty products, and oils. There is no abuse potential
or medicinal benefit from hemp or hemp products 24.
Female flowers produce recreational and medicinal drugs, edible seeds, and essential oils
24

. Dried leaves and flowers are smoked for their euphoric and relaxing enhancing properties 24.

Cannabidiol (CBD) and, Δ9-tetrahydrocannabinol (THC) are the most commonly researched
cannabinoids. In 1940, CBD was extracted from the cannabis plant and was found to have no
psychotropic effects 25. In 1964, THC, the primary psychotropic cannabinoid, was discovered
and ECS research gained momentum 14.
CBD targets CB2Rs with an agonizing effect. Since CBD has very little impact on
CB1Rs, the psychoactive side effects are minimized. Colorado researchers manipulated cannabis
plant genetics to remove THC in an attempt to develop pediatric epilepsy medical cannabis. The
cannabis was found to be ineffective. It was discovered the cannabinoids work better together
and produce a synergistic effect which leads to improved clinical outcomes 26.
This finding led to the development of the specialized medical cannabis, Charlotte’s
Web, which is an example of medical cannabis high in CBD and low in THC (<.3%). This
unique formula maintains better seizure control with minimal psychoactive side effects 26.
Since 2014, GW Pharmaceuticals has been testing another medical cannabis drug called
Epidiolex which has a 99% CBD concentration and <10% THC content. It is being used to treat
Dravet Syndrome which is a rare form of epilepsy. In March 2016, the company reported its
Phase 3 Clinical Trials which showed some promising results. They reported almost a 40%
decrease in monthly convulsive seizures among their participants 27. Their study was performed
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on children between the ages of 6-10 who had previously been on multiple anticonvulsants
which had failed to adequately control their seizures. Their goal is to be the first cannabis based
drug approved by the FDA for seizure control in children with epilepsy 27.
Medical Cannabis Research
Besides research on the use of cannabinoids as anticonvulsant agents, many other ECS
research studies are being done. Animal model research suggests the ECS may have an important
role in the creation, maintenance, and expenditure of energy 16. Another study linked CB1Rs to
the health and maintenance of kidneys 28. The study revealed that kidney fibrosis, which often
occurs in kidney disease and diabetes, was worse in the presence of CB1R activation in kidney
tissues. In mice, when CB1Rs were blocked, it resulted in a significant decrease in kidney
fibrosis and renal scarring 28. Some researchers believe medical conditions, such as weight loss
and diabetes, may someday be controlled through CB1R manipulation 16.
According to a recent clinical review, compelling evidence suggests medical cannabis
may show promise in areas of chronic pain and spasticity associated with multiple sclerosis.
Both of these conditions would use THC as the primary effector 23.
Recent research is examining the role of CB1Rs and cannabinoids in the treatment of
Post-Traumatic Stress Disorder (PTSD) in the veteran population. There are known elevated
numbers of brain CB1Rs associated with PTSD 29. Currently there is a $2,156,000 grant research
project, the Marijuana for Symptoms of PTSD in U.S. Veterans, being carried out 30.
Other research is examining the effects of THC on the treatment of memory loss and
Alzheimer’s disease. Animal model research demonstrates THC competitively inhibits the
enzyme acetylcholinesterase and decreases amyloid β-peptide aggregation which is a key marker
of Alzheimer’s disease 31.
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Cannabinoids and their receptors are also being studied for their roles in cancer tumor
growths. Animal tumor models suggest endocannabinoids may inhibit neo-angiogenesis and
tumor cell migration. These actions may be receptor-independent based on the type of tumor or
tissue cell and the cannabinoid or endocannabinoid expressed 32.
In order for these studies to take place cannabis need to be legally grown, harvested and
supplied to research institutions here in the US. Over the years, researchers have struggled
gaining access to medical cannabis in order to complete these studies. Medical cannabis has been
used for research and clinical trials in animals, but human studies have been restricted by
cannabis’ Schedule 1 drug listing under federal law and the negative stigmatism cannabis among
the general population. This severely limited the availability of research grown cannabis. Since
the 1960’s, the federal government has only approved the University of Mississippi’s (U of M)
School of Pharmacy to grow cannabis. In 2013, U of M had about 34 pounds of medical
cannabis available for researchers. Today there are over twelve acres and an indoor nursery,
which together, provide about 1400 pounds of cannabis grown solely for medical research and
scientific studies 26. With the significant increase in cannabis research, Drug Enforcement
Administration is again reviewing the possibility of changing cannabis from a Schedule 1 to a
Schedule 2 drug classification 33.
The botanists at the University of Mississippi work closely with pharmaceutical
companies and researchers in order to provide crops to meet their unique and specific needs for
the illness they are targeting. The scientists genetically modify the cannabis plant concentrations
of THC and CBD 26. Once the cannabinoid strains are chosen and procured for medical use, drug
companies must then decide on the mechanism of delivery and which biochemical form they
would like to use.
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Health-Care Provider Concerns
If research continues in the direction it is heading, then providers will need to decide how
they want to proceed if asked to prescribe cannabis-based drugs. There are numerous concerns
regarding cannabis use if laws and regulations remain the same. Providers may face certain
challenges should they choose to prescribe cannabis for their patients. For example, as long as
federal law defines cannabis as a Schedule I drug then states which have legalized cannabis are
in direct conflict with federal law. Today, medical cannabis is legalized in 25 states and the
District of Columbia. Despite having state law approval, providers could be subject to
prosecution according to federal laws. However, most federal law enforcement agencies have left
the policing of in-state marijuana cases to state authorities, resulting in national prosecutors
refraining from pursuing states and their medical providers who are currently prescribing
medical cannabis34. Yet, this does not alleviate the risk a provider takes when prescribing
medical cannabis since the federal government could decide to take a new position on
enforcement at any time 35.
Health care providers must also be concerned with state specific regulations. In states
where medical cannabis use has been legalized, there is no medical practice standardization
across state lines. Each state determines the medical conditions which may or may not be treated.
Often these conditions include a handful of serious illnesses which have failed to respond to
conventional treatment modalities. This makes it difficult to provide continuity of care to patients
who have moved from one state to another. The provider must also be aware and compliant with
the state mandated medical documentation requirements which include the frequency of reevaluation for the medical condition being treated. Many states also differ in who can prescribe
cannabis. Some states may only allow certain specialists, such as neurologists and oncologists, to
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prescribe cannabis medications. Qualified providers then write a recommendation stating the
patient would benefit from medical cannabis 35. However, without FDA guidelines and the
standardization of medical cannabis drugs, patients and providers are left to determine proper
dosing regimens on their own.
Once patients receive their medication, struggles may persist as far as who can administer
it and when it can be taken. The continued conflict between state and federal laws may put
nurses and parents who administer medical cannabis at risk for legal prosecution. For example,
Colorado is currently reviewing its laws on allowing students with valid prescriptions to use
edible medicinal cannabis at public schools. The Colorado law states it is permissible for the
school nurse or parent to administer the medicinal cannabis as long as the school district agrees.
Currently no school district has given its approval. Additionally, school nurses are in conflict
because they are required by federal law to report to authorities any child exposed to illegal
drugs which include cannabis derived preparations 36.
These regulatory inconsistencies between state and federal law leave many health care
providers reluctant to offer cannabis based medicines even when it may be justified and the best
available option for the patient. Providers also fear it puts the patient at risk since human
research cannabis trials are limited and there is no standardization to medical cannabis drug
regimens.
Conclusion
It is important for health care providers to understand the basic functioning of the ECS
and its potential to treat many disease processes. Up to now medical cannabis research, with
human subjects, has been limited by federal law and the availability of government sanctioned
research on cannabis. As the interest in cannabis medical research increases, and involvement of
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pharmaceutical companies in developing cannabis based treatments grows, further research
needs to be expanded to include human subjects. This comes at a time in American culture when
there is a strong movement to discuss and legalize cannabis for both medical and recreational
use. Currently, four states have legalized cannabis for recreational use while 25 states have laws
sanctioning medical applications 37.
This has led to continued state and national debates to change cannabis from a Schedule 1
to Schedule 2 drug. While states continue to legalize medical cannabis, there is inconsistency in
law and policies and direct conflict with federal laws. It is hoped that a resolution will occur in
which the federal government will allow quality cannabis medical research to be done to
determine the actual value of cannabis in treating human disease processes.
Health care providers need to understand the legal ramifications of prescribing cannabisbased drugs. It is hoped as the conflict resolves and quality cannabis research is carried out. The
ECS and cannabis-based drugs will offer new treatment options for patients with serious diseases
refractory to conventional treatments.
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